Reprograms immunity for cancer immunotherapy using synthetic RNA encoding a replication-limited viral blueprint delivered via precision lipid nanoparticles (LNPs). One-cycle RNA platform converts tumors into immune-activation sites to elicit full cellular and antibody responses with intrinsic safety; proof-of-concept shows in vitro potency and tumor-targeted delivery in vivo.